February 16, 2015

Aravis to present at the Innovationsforum Energie in Zurich on the 20th of March

Aravis has been invited to speak at the 5th Innovationsforum Energie in Zurich on 20th March 2015. Besides sharing practical insights from Aravis experiences in Investment in the energy sector, the following pertinent issues will be addressed:
- Analysing the market to ascertain what is the appetite of investors for European Infrastructure;
- How do Financial Investors view investments in the Energy sector today;
- What are some possible collaborations models between utilities and financial investors when financing energy infrastructure projects?

read more »

February 13, 2015

Bellerophon Therapeutics Announces Pricing of Its Initial Public Offering

Bellerophon Therapeutics announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Bellerophon. In addition, Bellerophon has granted the underwriters an option to purchase up to 750,000 additional shares of common stock at the public offering price, less the underwriting discount.  Bellerophon's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "BLPH" on February 13, 2015.  The offering is expected to close on February 19, 2015, subject to customary closing conditions.
PDF Download

read more »

February 12, 2015

MerLion announces FDA approval of finafloxacin otic suspension - First novel drug from a Singapore company to achieve FDA approval

MerLion Pharmaceuticals (MerLion), a biopharmaceutical company headquartered in Singapore with clinical development operations in Berlin, Germany, today announced that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa, commonly known as “swimmer’s ear”, caused by Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in North America for otic (ear) infections.
PDF Download

read more »

February 09, 2015

Evolva provides financial and project update

Evolva (SIX: EVE) today provides a financial and project update.According to the provisional, unaudited financials, revenues in 2014 slightly exceeded CHF 10 million (in line with guidance), whilst the year-end cash position of CHF 60.7 million was higher than the CHF 50 million projected in November 2014.
PDF Download - English Version
PDF Download - German Version
 

read more »

January 29, 2015

Aravis sponsors the Wind Risk Management and Mitigation Forum in London on the 4th and 5th of February

Aravis is proud to sponsor the Wind Risk Management and Mitigation Forum taking place in London on the 4th and 5th of February. The conference is organised by Wind Power Monthly, which is widely regarded as the most prestigious magazine in the wind energy sector. In addition, on the second day Aravis will be presenting the topic “Assessing The Impact Of Weather Risk On Cash Flow”. We are excited about the event and are looking forward to meeting you at the conference.

read more »

January 19, 2015

Evolva and Cargill to collaborate on second family of ingredients

Evolva Holding SA (“Evolva”; SIX: EVE) and Cargill have signed an agreement to co-develop a sustainable, customisable, and cost-effective fermentation production process for a second family of high-value food and beverage ingredients.
PDF Download - English Version
PDF Download - German Version

read more »

January 08, 2015

Evolva and L’Oréal reach first milestone in innovative cosmetics ingredient project

Evolva Holding SA (SIX: EVE) today announces the successful completion of the first part of its R&D collaboration with L’Oréal. The parties have agreed to move into the next phase of the multi-year programme.
PDF Download - English Version
PDF Download - German Version

read more »